aTyr Pharma to Present Three Posters for Efzofitimod at the American Thoracic Society (ATS) 2025 International Conference
aTyr Pharma (ATYR) has announced its upcoming presentation of three posters featuring efzofitimod at the American Thoracic Society (ATS) 2025 International Conference in San Francisco from May 16-21, 2025. The presentations will cover:
1. The EFZO-FIT trial design and patient characteristics, showcasing the largest placebo-controlled trial in pulmonary sarcoidosis
2. Real-world treatment patterns among pulmonary sarcoidosis patients in the US
3. Incidence, prevalence, and mortality data for pulmonary sarcoidosis with parenchymal involvement in the US
Efzofitimod, their lead therapeutic candidate, is a first-in-class biologic immunomodulator being developed for interstitial lung disease (ILD). It's currently under investigation in two clinical trials: the global Phase 3 EFZO-FIT™ study for pulmonary sarcoidosis and the Phase 2 EFZO-CONNECT™ study for systemic sclerosis-related ILD. Topline data from the Phase 3 study is expected in Q3 2025.
aTyr Pharma (ATYR) ha annunciato la sua prossima presentazione di tre poster riguardanti efzofitimod alla Conferenza Internazionale della Società Toracica Americana (ATS) 2025, che si terrà a San Francisco dal 16 al 21 maggio 2025. Le presentazioni riguarderanno:
1. Il design dello studio EFZO-FIT e le caratteristiche dei pazienti, mettendo in evidenza il più grande studio controllato con placebo nella sarcoidosi polmonare
2. Schemi di trattamento nel mondo reale tra i pazienti con sarcoidosi polmonare negli Stati Uniti
3. Dati su incidenza, prevalenza e mortalità per la sarcoidosi polmonare con coinvolgimento parenchimatoso negli Stati Uniti
Efzofitimod, il loro principale candidato terapeutico, è un immunomodulatore biologico di prima classe in fase di sviluppo per le malattie polmonari interstiziali (ILD). È attualmente oggetto di indagini in due studi clinici: lo studio globale di Fase 3 EFZO-FIT™ per la sarcoidosi polmonare e lo studio di Fase 2 EFZO-CONNECT™ per ILD correlato alla sclerosi sistemica. I dati preliminari dello studio di Fase 3 sono attesi nel terzo trimestre del 2025.
aTyr Pharma (ATYR) ha anunciado su próxima presentación de tres carteles sobre efzofitimod en la Conferencia Internacional de la Sociedad Torácica Americana (ATS) 2025 que se llevará a cabo en San Francisco del 16 al 21 de mayo de 2025. Las presentaciones cubrirán:
1. El diseño del ensayo EFZO-FIT y las características del paciente, destacando el mayor ensayo controlado con placebo en sarcoidosis pulmonar
2. Patrones de tratamiento en la vida real entre pacientes con sarcoidosis pulmonar en EE. UU.
3. Datos de incidencia, prevalencia y mortalidad para la sarcoidosis pulmonar con involucramiento parenquimatoso en EE. UU.
Efzofitimod, su principal candidato terapéutico, es un inmunomodulador biológico de primera clase que se está desarrollando para la enfermedad intersticial pulmonar (ILD). Actualmente se está investigando en dos ensayos clínicos: el estudio global de Fase 3 EFZO-FIT™ para la sarcoidosis pulmonar y el estudio de Fase 2 EFZO-CONNECT™ para ILD relacionada con esclerosis sistémica. Se esperan datos preliminares del estudio de Fase 3 en el tercer trimestre de 2025.
aTyr Pharma (ATYR)는 2025년 5월 16일부터 21일까지 샌프란시스코에서 열리는 미국 흉부학회 (ATS) 2025 국제 회의에서 efzofitimod에 대한 세 가지 포스터를 발표할 예정이라고 발표했습니다. 발표 내용은 다음과 같습니다:
1. 폐사르코이드증에서 가장 큰 위약 대조 시험을 보여주는 EFZO-FIT 시험 설계 및 환자 특성
2. 미국 폐사르코이드증 환자들 사이의 실제 치료 패턴
3. 미국의 폐사르코이드증에서의 실질적 관련성을 포함한 발병률, 유병률 및 사망률 데이터
efzofitimod는 그들의 주요 치료 후보로, 간질성 폐질환(ILD)을 위해 개발 중인 1세대 생물학적 면역 조절제입니다. 현재 폐사르코이드증에 대한 글로벌 3상 EFZO-FIT™ 연구와 전신경화증 관련 ILD에 대한 2상 EFZO-CONNECT™ 연구에서 조사되고 있습니다. 3상 연구의 주요 데이터는 2025년 3분기에 발표될 예정입니다.
aTyr Pharma (ATYR) a annoncé sa prochaine présentation de trois affiches concernant efzofitimod lors de la Conférence Internationale de la Société Thoracique Américaine (ATS) 2025 qui se tiendra à San Francisco du 16 au 21 mai 2025. Les présentations porteront sur :
1. La conception de l'essai EFZO-FIT et les caractéristiques des patients, mettant en avant le plus grand essai contrôlé par placebo chez les patients atteints de sarcoïdose pulmonaire
2. Les schémas de traitement dans le monde réel chez les patients atteints de sarcoïdose pulmonaire aux États-Unis
3. Les données d'incidence, de prévalence et de mortalité pour la sarcoïdose pulmonaire avec implication parenchymateuse aux États-Unis
Efzofitimod, leur principal candidat thérapeutique, est un immunomodulateur biologique de première classe en cours de développement pour les maladies pulmonaires interstitielles (ILD). Il est actuellement à l'étude dans deux essais cliniques : l'étude mondiale de Phase 3 EFZO-FIT™ pour la sarcoïdose pulmonaire et l'étude de Phase 2 EFZO-CONNECT™ pour l'ILD liée à la sclérodermie systémique. Les données préliminaires de l'étude de Phase 3 sont attendues au troisième trimestre 2025.
aTyr Pharma (ATYR) hat die bevorstehende Präsentation von drei Postern über efzofitimod auf der Amerikanischen Thoraxgesellschaft (ATS) 2025 Internationalen Konferenz in San Francisco vom 16. bis 21. Mai 2025 angekündigt. Die Präsentationen werden folgende Themen abdecken:
1. Das Studiendesign EFZO-FIT und die Patientenmerkmale, das die größte Placebo-kontrollierte Studie bei pulmonaler Sarcoidose präsentiert
2. Echtwelt-Behandlungsanalysen bei Patienten mit pulmonaler Sarcoidose in den USA
3. Inzidenz-, Prävalenz- und Mortalitätsdaten für die pulmonale Sarcoidose mit parenchymaler Beteiligung in den USA
Efzofitimod, ihr führender therapeutischer Kandidat, ist ein erstklassiger biologischer Immunmodulator, der für interstitielle Lungenerkrankungen (ILD) entwickelt wird. Es wird derzeit in zwei klinischen Studien untersucht: der globalen Phase-3-Studie EFZO-FIT™ für pulmonale Sarcoidose und der Phase-2-Studie EFZO-CONNECT™ für ILD im Zusammenhang mit systemischer Sklerose. Die Hauptdaten aus der Phase-3-Studie werden im 3. Quartal 2025 erwartet.
- None.
- None.
Blinded baseline demographics and disease characteristics for ongoing Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis; topline data from the study expected in the third quarter of 2025
Current epidemiology and treatment practices for pulmonary sarcoidosis in the U.S. based on real-world evidence
SAN DIEGO, Jan. 29, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the company will present three posters for its lead therapeutic candidate, efzofitimod, at the American Thoracic Society (ATS) 2025 International Conference, which is scheduled to take place May 16 – 21, 2025, in San Francisco, CA.
Preliminary details of the poster presentations appear below. The posters will be available on the aTyr website once presented.
Title: EFZO-FIT, Largest Placebo-Controlled Trial in Pulmonary Sarcoidosis – Trial Design and Patient Characteristics
Session: Repair My Broken Lungs
Date and Time: Monday, May 19, 2025 from 9:15AM – 4:15PM PT
Location: Moscone Center, San Francisco, CA
Title: Real-World Treatment Patterns Among Pulmonary Sarcoidosis Patients with Parenchymal Involvement in the US
Session: The Inflamed Lung: Sarcoidosis and Autoimmune Disease
Date and Time: Sunday, May 18, 2025 from 9:15AM – 4:15PM PT
Location: Moscone Center, San Francisco, CA
Title: Incidence, Prevalence, and Mortality of Pulmonary Sarcoidosis with Parenchymal Involvement in the US
Session: Current Insights into Risk, Diagnosis, and Treatment of Occupational and Environmental Lung Diseases
Date and Time: Tuesday, May 20, 2025 from 9:15AM – 4:15PM PT
Location: Moscone Center, San Francisco, CA
About Efzofitimod
Efzofitimod is a first-in-class biologic immunomodulator in clinical development for the treatment of interstitial lung disease (ILD), a group of immune-mediated disorders that can cause inflammation and fibrosis, or scarring, of the lungs. Efzofitimod is a tRNA synthetase derived therapy that selectively modulates activated myeloid cells through neuropilin-2 to resolve inflammation without immune suppression and potentially prevent the progression of fibrosis. aTyr is currently investigating efzofitimod in the global Phase 3 EFZO-FIT™ study in patients with pulmonary sarcoidosis, a major form of ILD, and in the Phase 2 EFZO-CONNECT™ study in patients with systemic sclerosis (SSc, or scleroderma)-related ILD. These forms of ILD have limited therapeutic options and there is a need for safer and more effective, disease-modifying treatments that improve outcomes.
About aTyr
aTyr is a clinical stage biotechnology company leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. tRNA synthetases are ancient, essential proteins that have evolved novel domains that regulate diverse pathways extracellularly in humans. aTyr’s discovery platform is focused on unlocking hidden therapeutic intervention points by uncovering signaling pathways driven by its proprietary library of domains derived from all 20 tRNA synthetases. aTyr’s lead therapeutic candidate is efzofitimod, a first-in-class biologic immunomodulator in clinical development for the treatment of interstitial lung disease, a group of immune-mediated disorders that can cause inflammation and progressive fibrosis, or scarring, of the lungs. For more information, please visit www.atyrpharma.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are usually identified by the use of words such as "anticipate," “believes,” “designed,” “could” “can,” “expects,” “intends,” “may,” “plans,” “potential,” “will,” and variations of such words or similar expressions. We intend these forward-looking statements to be covered by such safe harbor provisions for forward-looking statements and are making this statement for purposes of complying with those safe harbor provisions. These forward-looking statements include, among others, statements regarding the clinical development for efzofitimod, including our expectations with respect to the baseline demographic and patient characteristics, conduct, timing and results of EFZO-FIT™, and the epidemiology and treatment practices for pulmonary sarcoidosis in the U.S. These forward-looking statements also reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies and prospects, as reflected in or suggested by these forward-looking statements, are reasonable, we can give no assurance that the plans, intentions, expectations, strategies or prospects will be attained or achieved. All forward-looking statements are based on estimates and assumptions by our management that, although we believe to be reasonable, are inherently uncertain. Furthermore, actual results may differ materially from those described in these forward-looking statements and will be affected by a variety of risks and factors that are beyond our control including, without limitation, uncertainty regarding geopolitical and macroeconomic events, risks associated with the discovery, development and regulation of efzofitimod, the risk that we or our partners may cease or delay preclinical or clinical development activities for efzofitimod for a variety of reasons (including difficulties or delays in patient enrollment in planned clinical trials), the possibility that existing collaborations could be terminated early, and the risk that we may not be able to raise the additional funding required for our business and product development plans, as well as those risks set forth in our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and in our other SEC filings. Except as required by law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
Contact:
Ashlee Dunston
Sr. Director, Investor Relations and Public Affairs
adunston@atyrpharma.com
FAQ
When will aTyr Pharma (ATYR) release topline data for the Phase 3 EFZO-FIT study?
What clinical trials is efzofitimod currently being tested in by ATYR?
What will ATYR present at the ATS 2025 International Conference?
How does efzofitimod work in treating interstitial lung disease?
When and where will ATYR present their efzofitimod research at ATS 2025?
